‘Huh?’ Markets React to AstraZeneca’s Megadeal Talks With Bristol Myers
Britannia might lose its cool over this one. A day after the Financial Times reported $264 billion UK…
AstraZeneca in Talks to Merge With Bristol Myers Squibb in Potential $400B Pharma Megadeal — BigGo Finance
UK drugmaker AstraZeneca has held exploratory talks with US rival Bristol Myers Squibb about a potential merger that…
Pfizer (PFE) Gets An Opening In ATTR CM After AstraZeneca Trial Failure
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
AstraZeneca’s $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw — BigGo Finance
For AstraZeneca, July 9 was a $27 billion disaster. Its gene-silencing heart drug, eplontersen, had just flopped in…
AstraZeneca Plunges After New Heart Disease Drug Fails Trial
It was just another manic market day, at least for AstraZeneca. Shares of the British-Swedish biopharmaceutical company tumbled…
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
Pfizer PFE and AstraZeneca AZN are global pharmaceutical leaders with a strong presence in oncology. For Pfizer, oncology…
HSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalyst
HSBC analyst Rajesh Kumar downgraded Pfizer Inc. (NYSE: PFE) from Buy to Hold on Monday, cutting the bank’s…
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
Key Points Interested in Nuvalent, Inc.? Here are five stocks we like better. GSK agreed to acquire Nuvalent…
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments
Two GlaxoSmithKline (GSK) R&D team members at work in the company’s Upper Merion, PA, laboratory. GSK has agreed…